| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Neuroblastoma | 46 | 2026 | 547 | 6.750 |
Why?
|
| Watchful Waiting | 2 | 2025 | 73 | 1.210 |
Why?
|
| Wilms Tumor | 8 | 2023 | 117 | 1.080 |
Why?
|
| Tumor Suppressor Protein p53 | 5 | 2016 | 720 | 0.950 |
Why?
|
| Infant | 60 | 2026 | 13266 | 0.870 |
Why?
|
| Child | 81 | 2026 | 26169 | 0.810 |
Why?
|
| Doxorubicin | 8 | 2019 | 289 | 0.810 |
Why?
|
| Child, Preschool | 58 | 2026 | 15002 | 0.800 |
Why?
|
| Survival Rate | 19 | 2025 | 2108 | 0.760 |
Why?
|
| Specialties, Surgical | 3 | 2023 | 90 | 0.750 |
Why?
|
| Etoposide | 4 | 2019 | 111 | 0.690 |
Why?
|
| Hepatoblastoma | 6 | 2026 | 204 | 0.680 |
Why?
|
| Ubiquitin Thiolesterase | 2 | 2019 | 65 | 0.680 |
Why?
|
| Cell Proliferation | 10 | 2019 | 2462 | 0.660 |
Why?
|
| Magnets | 1 | 2020 | 22 | 0.650 |
Why?
|
| Infant, Newborn | 33 | 2025 | 8545 | 0.650 |
Why?
|
| Prognosis | 19 | 2026 | 4851 | 0.640 |
Why?
|
| Foreign Bodies | 2 | 2020 | 97 | 0.630 |
Why?
|
| Humans | 142 | 2026 | 130066 | 0.630 |
Why?
|
| Apoptosis | 8 | 2019 | 1826 | 0.620 |
Why?
|
| Retroperitoneal Neoplasms | 2 | 2013 | 28 | 0.620 |
Why?
|
| Kidney Neoplasms | 7 | 2023 | 420 | 0.620 |
Why?
|
| Neoplasm Staging | 19 | 2026 | 1278 | 0.620 |
Why?
|
| Adolescent | 53 | 2026 | 20797 | 0.600 |
Why?
|
| Piperidones | 1 | 2019 | 9 | 0.590 |
Why?
|
| Appendectomy | 6 | 2021 | 88 | 0.590 |
Why?
|
| Carcinoma, Mucoepidermoid | 2 | 2016 | 16 | 0.580 |
Why?
|
| Appendicitis | 6 | 2021 | 132 | 0.580 |
Why?
|
| Follow-Up Studies | 17 | 2026 | 5167 | 0.580 |
Why?
|
| Retrospective Studies | 52 | 2026 | 17537 | 0.550 |
Why?
|
| Male | 93 | 2026 | 64378 | 0.550 |
Why?
|
| Analgesia, Epidural | 3 | 2022 | 30 | 0.520 |
Why?
|
| Adrenal Gland Neoplasms | 2 | 2021 | 63 | 0.520 |
Why?
|
| Female | 83 | 2026 | 70239 | 0.520 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 2 | 2016 | 79 | 0.510 |
Why?
|
| Carcinoma | 4 | 2016 | 283 | 0.510 |
Why?
|
| Spiro Compounds | 1 | 2016 | 12 | 0.510 |
Why?
|
| Antineoplastic Agents | 11 | 2021 | 1800 | 0.500 |
Why?
|
| Indoles | 2 | 2016 | 200 | 0.500 |
Why?
|
| Checkpoint Kinase 2 | 1 | 2016 | 36 | 0.500 |
Why?
|
| Xenograft Model Antitumor Assays | 6 | 2021 | 1001 | 0.490 |
Why?
|
| Dipeptides | 1 | 2016 | 60 | 0.490 |
Why?
|
| Aminopyridines | 1 | 2016 | 63 | 0.490 |
Why?
|
| Bronchial Neoplasms | 1 | 2016 | 15 | 0.470 |
Why?
|
| Tracheal Neoplasms | 1 | 2016 | 21 | 0.470 |
Why?
|
| Liver Neoplasms | 8 | 2026 | 1366 | 0.460 |
Why?
|
| Surgeons | 2 | 2021 | 289 | 0.450 |
Why?
|
| Disease-Free Survival | 13 | 2026 | 902 | 0.450 |
Why?
|
| Teaching Rounds | 1 | 2015 | 30 | 0.450 |
Why?
|
| Funnel Chest | 3 | 2022 | 33 | 0.440 |
Why?
|
| Soft Tissue Neoplasms | 3 | 2022 | 124 | 0.440 |
Why?
|
| Cell Line, Tumor | 12 | 2019 | 3712 | 0.420 |
Why?
|
| Cost Savings | 3 | 2021 | 79 | 0.410 |
Why?
|
| Kaplan-Meier Estimate | 8 | 2025 | 1070 | 0.400 |
Why?
|
| Neoplasm Proteins | 4 | 2011 | 679 | 0.380 |
Why?
|
| Cell Survival | 5 | 2019 | 827 | 0.370 |
Why?
|
| Lung Neoplasms | 4 | 2017 | 1545 | 0.370 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 3 | 2017 | 92 | 0.370 |
Why?
|
| Sarcoma | 3 | 2022 | 218 | 0.360 |
Why?
|
| Macaca mulatta | 15 | 2011 | 492 | 0.360 |
Why?
|
| Bone Marrow Neoplasms | 3 | 2017 | 22 | 0.360 |
Why?
|
| T-Lymphocytes, Cytotoxic | 5 | 2002 | 510 | 0.360 |
Why?
|
| Genes, myc | 3 | 2012 | 96 | 0.360 |
Why?
|
| Drug Resistance, Neoplasm | 8 | 2019 | 816 | 0.350 |
Why?
|
| Treatment Outcome | 30 | 2026 | 12818 | 0.350 |
Why?
|
| Rhabdomyosarcoma | 3 | 2021 | 229 | 0.350 |
Why?
|
| Mice, Nude | 6 | 2019 | 699 | 0.340 |
Why?
|
| Thoracic Neoplasms | 4 | 2021 | 36 | 0.340 |
Why?
|
| Ovarian Neoplasms | 3 | 2017 | 421 | 0.330 |
Why?
|
| Biomarkers, Tumor | 7 | 2022 | 1582 | 0.330 |
Why?
|
| Brain Neoplasms | 2 | 2016 | 1305 | 0.320 |
Why?
|
| Quality Improvement | 2 | 2016 | 708 | 0.320 |
Why?
|
| Combined Modality Therapy | 10 | 2023 | 1212 | 0.320 |
Why?
|
| Drug Synergism | 4 | 2019 | 236 | 0.310 |
Why?
|
| Catheters, Indwelling | 4 | 2016 | 140 | 0.310 |
Why?
|
| Databases, Factual | 9 | 2019 | 1227 | 0.310 |
Why?
|
| Neoplasm Recurrence, Local | 5 | 2015 | 1265 | 0.300 |
Why?
|
| Survival Analysis | 9 | 2019 | 1481 | 0.280 |
Why?
|
| Surgical Procedures, Operative | 2 | 2025 | 225 | 0.280 |
Why?
|
| Neuroendocrine Tumors | 3 | 2019 | 70 | 0.270 |
Why?
|
| Pancreatic Neoplasms | 3 | 2022 | 735 | 0.270 |
Why?
|
| Laparoscopy | 5 | 2018 | 535 | 0.270 |
Why?
|
| Risk Assessment | 10 | 2026 | 3678 | 0.270 |
Why?
|
| Pediatrics | 3 | 2017 | 1242 | 0.260 |
Why?
|
| Healthcare Disparities | 3 | 2017 | 513 | 0.260 |
Why?
|
| Hepatectomy | 2 | 2026 | 130 | 0.260 |
Why?
|
| Postoperative Complications | 13 | 2026 | 3114 | 0.260 |
Why?
|
| Biopsy | 6 | 2018 | 1240 | 0.250 |
Why?
|
| Time Factors | 9 | 2025 | 6165 | 0.250 |
Why?
|
| Hospital Costs | 3 | 2017 | 184 | 0.250 |
Why?
|
| Bone Neoplasms | 2 | 2017 | 469 | 0.240 |
Why?
|
| Protein Kinase Inhibitors | 4 | 2017 | 613 | 0.240 |
Why?
|
| Skin Neoplasms | 3 | 2025 | 903 | 0.240 |
Why?
|
| Postoperative Care | 2 | 2026 | 294 | 0.240 |
Why?
|
| Adenomatous Polyposis Coli | 1 | 2006 | 44 | 0.230 |
Why?
|
| Appendiceal Neoplasms | 2 | 2017 | 20 | 0.230 |
Why?
|
| Organ Sparing Treatments | 1 | 2026 | 44 | 0.230 |
Why?
|
| Prosthesis Implantation | 2 | 2013 | 151 | 0.230 |
Why?
|
| Thyroidectomy | 2 | 2017 | 96 | 0.230 |
Why?
|
| Gene Expression Regulation, Neoplastic | 6 | 2016 | 2009 | 0.230 |
Why?
|
| Basal Cell Nevus Syndrome | 1 | 2025 | 15 | 0.230 |
Why?
|
| Nephrectomy | 5 | 2023 | 156 | 0.220 |
Why?
|
| Carcinoma, Adenoid Cystic | 1 | 2025 | 33 | 0.220 |
Why?
|
| Hemangioma | 1 | 2006 | 86 | 0.220 |
Why?
|
| Gene Amplification | 3 | 2012 | 219 | 0.210 |
Why?
|
| Antibiotics, Antineoplastic | 3 | 2019 | 122 | 0.210 |
Why?
|
| Membrane Proteins | 2 | 2009 | 1589 | 0.210 |
Why?
|
| Adenocarcinoma, Mucinous | 2 | 2015 | 37 | 0.210 |
Why?
|
| Pneumonectomy | 2 | 2016 | 154 | 0.210 |
Why?
|
| Receptors, CXCR4 | 1 | 2004 | 69 | 0.210 |
Why?
|
| Tomography, X-Ray Computed | 8 | 2016 | 2057 | 0.210 |
Why?
|
| Animals | 29 | 2021 | 33641 | 0.200 |
Why?
|
| Patient Admission | 1 | 2025 | 184 | 0.200 |
Why?
|
| Medical Oncology | 1 | 2025 | 241 | 0.200 |
Why?
|
| Thyroid Neoplasms | 2 | 2017 | 243 | 0.200 |
Why?
|
| Ganglioneuroma | 2 | 2021 | 15 | 0.190 |
Why?
|
| DNA-Binding Proteins | 3 | 2011 | 1931 | 0.190 |
Why?
|
| Fibroma | 1 | 2022 | 29 | 0.180 |
Why?
|
| Tumor Burden | 3 | 2019 | 237 | 0.180 |
Why?
|
| Catheterization, Central Venous | 2 | 2014 | 136 | 0.180 |
Why?
|
| Induction Chemotherapy | 2 | 2020 | 55 | 0.180 |
Why?
|
| Surgical Oncology | 1 | 2022 | 15 | 0.180 |
Why?
|
| United States | 13 | 2023 | 11893 | 0.180 |
Why?
|
| Abdominal Neoplasms | 3 | 2012 | 31 | 0.180 |
Why?
|
| Fetal Diseases | 1 | 2006 | 439 | 0.180 |
Why?
|
| Cryosurgery | 1 | 2022 | 51 | 0.180 |
Why?
|
| Risk Factors | 8 | 2026 | 10959 | 0.180 |
Why?
|
| Hemangiosarcoma | 1 | 2022 | 47 | 0.170 |
Why?
|
| Ganglioneuroblastoma | 1 | 2021 | 7 | 0.170 |
Why?
|
| HLA-A2 Antigen | 1 | 2001 | 25 | 0.170 |
Why?
|
| Cell Cycle Proteins | 2 | 2006 | 705 | 0.170 |
Why?
|
| Pneumothorax | 2 | 2020 | 78 | 0.170 |
Why?
|
| MyoD Protein | 1 | 2021 | 22 | 0.170 |
Why?
|
| Health Services Accessibility | 2 | 2025 | 698 | 0.170 |
Why?
|
| RNA, Messenger | 3 | 2015 | 2550 | 0.170 |
Why?
|
| Histocompatibility Antigens Class I | 3 | 1991 | 107 | 0.170 |
Why?
|
| MAP Kinase Kinase Kinases | 2 | 2013 | 56 | 0.170 |
Why?
|
| Ovariectomy | 1 | 2001 | 152 | 0.160 |
Why?
|
| Pancreatectomy | 3 | 2022 | 147 | 0.160 |
Why?
|
| Delivery of Health Care | 2 | 2017 | 683 | 0.160 |
Why?
|
| Nuclear Proteins | 3 | 2006 | 1207 | 0.160 |
Why?
|
| Jugular Veins | 1 | 2000 | 71 | 0.160 |
Why?
|
| Curriculum | 2 | 2023 | 792 | 0.160 |
Why?
|
| Hematopoietic Stem Cell Mobilization | 1 | 2020 | 27 | 0.160 |
Why?
|
| Histiocytosis | 1 | 2020 | 18 | 0.160 |
Why?
|
| Quinolines | 2 | 2021 | 115 | 0.160 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2020 | 91 | 0.160 |
Why?
|
| Hospital Mortality | 1 | 2025 | 1057 | 0.150 |
Why?
|
| Proportional Hazards Models | 7 | 2017 | 1393 | 0.150 |
Why?
|
| Tumor Cells, Cultured | 7 | 2004 | 975 | 0.150 |
Why?
|
| Age Factors | 8 | 2019 | 2822 | 0.150 |
Why?
|
| Telemedicine | 1 | 2026 | 525 | 0.150 |
Why?
|
| Global Burden of Disease | 1 | 2019 | 37 | 0.150 |
Why?
|
| Malawi | 3 | 2026 | 349 | 0.150 |
Why?
|
| Protein Unfolding | 1 | 2019 | 14 | 0.150 |
Why?
|
| Elective Surgical Procedures | 2 | 2019 | 161 | 0.150 |
Why?
|
| Pyrimidines | 2 | 2015 | 454 | 0.150 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2016 | 1604 | 0.150 |
Why?
|
| Global Health | 2 | 2021 | 622 | 0.150 |
Why?
|
| Texas | 6 | 2017 | 3655 | 0.140 |
Why?
|
| HEK293 Cells | 2 | 2019 | 800 | 0.140 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2000 | 186 | 0.140 |
Why?
|
| Bronchopulmonary Sequestration | 2 | 1997 | 5 | 0.140 |
Why?
|
| Neutropenia | 1 | 2020 | 209 | 0.140 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2019 | 100 | 0.140 |
Why?
|
| Ventriculoperitoneal Shunt | 1 | 2018 | 50 | 0.140 |
Why?
|
| Signal Transduction | 6 | 2017 | 4644 | 0.140 |
Why?
|
| Opioid-Related Disorders | 1 | 2022 | 296 | 0.140 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 5 | 2023 | 1325 | 0.140 |
Why?
|
| Adult | 21 | 2019 | 31012 | 0.140 |
Why?
|
| Young Adult | 12 | 2021 | 9981 | 0.140 |
Why?
|
| Inhibitory Concentration 50 | 2 | 2016 | 83 | 0.140 |
Why?
|
| Eating | 1 | 2020 | 374 | 0.140 |
Why?
|
| Gastrostomy | 1 | 2018 | 83 | 0.140 |
Why?
|
| Analgesics, Opioid | 5 | 2022 | 484 | 0.140 |
Why?
|
| Mice | 9 | 2021 | 18144 | 0.140 |
Why?
|
| Ambulatory Surgical Procedures | 1 | 2019 | 69 | 0.140 |
Why?
|
| Dysgerminoma | 1 | 2017 | 4 | 0.140 |
Why?
|
| Proto-Oncogene Proteins | 3 | 2022 | 598 | 0.140 |
Why?
|
| Age Distribution | 5 | 2016 | 421 | 0.130 |
Why?
|
| Gene Knockdown Techniques | 1 | 2019 | 378 | 0.130 |
Why?
|
| Research Design | 1 | 2022 | 710 | 0.130 |
Why?
|
| Area Under Curve | 10 | 2010 | 303 | 0.130 |
Why?
|
| Immunohistochemistry | 5 | 2017 | 1591 | 0.130 |
Why?
|
| Abdominal Pain | 2 | 2015 | 316 | 0.130 |
Why?
|
| Antimetabolites, Antineoplastic | 3 | 2006 | 194 | 0.130 |
Why?
|
| Peritoneum | 2 | 2016 | 34 | 0.130 |
Why?
|
| Bacterial Infections | 1 | 2020 | 327 | 0.130 |
Why?
|
| Proto-Oncogene Proteins c-abl | 1 | 2017 | 14 | 0.130 |
Why?
|
| Ambulatory Care Facilities | 1 | 2019 | 231 | 0.130 |
Why?
|
| Carcinoma, Lobular | 1 | 2017 | 26 | 0.130 |
Why?
|
| Fertility Preservation | 1 | 2017 | 61 | 0.120 |
Why?
|
| Aniline Compounds | 1 | 2017 | 23 | 0.120 |
Why?
|
| Hospitals, Low-Volume | 1 | 2016 | 36 | 0.120 |
Why?
|
| Interleukin-6 | 2 | 2008 | 410 | 0.120 |
Why?
|
| Testicular Neoplasms | 1 | 2017 | 112 | 0.120 |
Why?
|
| Pylorus | 3 | 2008 | 21 | 0.120 |
Why?
|
| src-Family Kinases | 1 | 2017 | 93 | 0.120 |
Why?
|
| Peptide Fragments | 1 | 2000 | 687 | 0.120 |
Why?
|
| Hospitals, High-Volume | 1 | 2016 | 44 | 0.120 |
Why?
|
| Health Status Disparities | 1 | 2019 | 278 | 0.120 |
Why?
|
| Efficiency, Organizational | 1 | 2016 | 55 | 0.120 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2017 | 86 | 0.120 |
Why?
|
| Lung Diseases | 1 | 2020 | 397 | 0.120 |
Why?
|
| Enteral Nutrition | 1 | 2018 | 286 | 0.120 |
Why?
|
| Kidney Failure, Chronic | 3 | 2016 | 930 | 0.120 |
Why?
|
| Arabinonucleosides | 2 | 2006 | 32 | 0.120 |
Why?
|
| Head and Neck Neoplasms | 2 | 2017 | 635 | 0.120 |
Why?
|
| Repressor Proteins | 2 | 2022 | 757 | 0.120 |
Why?
|
| Insurance Coverage | 1 | 2017 | 117 | 0.120 |
Why?
|
| Nitriles | 1 | 2017 | 161 | 0.120 |
Why?
|
| Education, Medical, Graduate | 1 | 2021 | 550 | 0.120 |
Why?
|
| Nurses, Pediatric | 1 | 2015 | 2 | 0.120 |
Why?
|
| Carcinoma, Signet Ring Cell | 1 | 2015 | 10 | 0.120 |
Why?
|
| Nasopharyngeal Neoplasms | 1 | 2016 | 57 | 0.120 |
Why?
|
| Internship and Residency | 2 | 2023 | 1217 | 0.120 |
Why?
|
| Cytotoxicity, Immunologic | 3 | 2002 | 271 | 0.120 |
Why?
|
| Metastasectomy | 1 | 2015 | 11 | 0.120 |
Why?
|
| Sarcoma, Clear Cell | 1 | 2015 | 20 | 0.120 |
Why?
|
| Intussusception | 2 | 2013 | 54 | 0.110 |
Why?
|
| Diagnosis, Differential | 5 | 2017 | 1873 | 0.110 |
Why?
|
| Adenoma, Liver Cell | 1 | 2015 | 3 | 0.110 |
Why?
|
| Positron-Emission Tomography | 1 | 2017 | 283 | 0.110 |
Why?
|
| Hernia, Abdominal | 1 | 2015 | 19 | 0.110 |
Why?
|
| Pneumoperitoneum | 2 | 2013 | 9 | 0.110 |
Why?
|
| Hospitals, Pediatric | 2 | 2015 | 800 | 0.110 |
Why?
|
| Benzoxazoles | 1 | 2015 | 11 | 0.110 |
Why?
|
| Ultrasonography | 4 | 2015 | 942 | 0.110 |
Why?
|
| Carcinoid Tumor | 1 | 2015 | 24 | 0.110 |
Why?
|
| Duodenal Diseases | 1 | 2015 | 28 | 0.110 |
Why?
|
| Hernia, Umbilical | 1 | 1995 | 40 | 0.110 |
Why?
|
| Hand Injuries | 1 | 1995 | 11 | 0.110 |
Why?
|
| Pneumonia | 2 | 2016 | 340 | 0.110 |
Why?
|
| Bronchogenic Cyst | 1 | 1994 | 8 | 0.110 |
Why?
|
| Job Satisfaction | 1 | 2015 | 99 | 0.110 |
Why?
|
| Genetic Markers | 1 | 2016 | 589 | 0.110 |
Why?
|
| Parathyroid Neoplasms | 1 | 2014 | 20 | 0.110 |
Why?
|
| Cystic Adenomatoid Malformation of Lung, Congenital | 1 | 1994 | 18 | 0.110 |
Why?
|
| Bronchoscopy | 1 | 2016 | 178 | 0.110 |
Why?
|
| Focal Nodular Hyperplasia | 1 | 2014 | 6 | 0.110 |
Why?
|
| Intestinal Volvulus | 1 | 2015 | 41 | 0.110 |
Why?
|
| Rectal Neoplasms | 1 | 2015 | 78 | 0.110 |
Why?
|
| Prospective Studies | 4 | 2024 | 6401 | 0.110 |
Why?
|
| Catheterization | 1 | 2016 | 225 | 0.110 |
Why?
|
| Parathyroidectomy | 1 | 2014 | 51 | 0.100 |
Why?
|
| Interprofessional Relations | 1 | 2015 | 149 | 0.100 |
Why?
|
| Peritoneal Dialysis | 1 | 2016 | 133 | 0.100 |
Why?
|
| Burns | 1 | 1995 | 89 | 0.100 |
Why?
|
| Incidence | 6 | 2019 | 3321 | 0.100 |
Why?
|
| Zearalenone | 1 | 2013 | 6 | 0.100 |
Why?
|
| Academic Medical Centers | 1 | 2015 | 320 | 0.100 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 1 | 2014 | 83 | 0.100 |
Why?
|
| Ubiquitin-Conjugating Enzymes | 1 | 2014 | 37 | 0.100 |
Why?
|
| Multiprotein Complexes | 1 | 2015 | 195 | 0.100 |
Why?
|
| Stomach Neoplasms | 2 | 2019 | 572 | 0.100 |
Why?
|
| Cohort Studies | 5 | 2017 | 5036 | 0.100 |
Why?
|
| Program Evaluation | 1 | 2015 | 443 | 0.100 |
Why?
|
| Lumbosacral Region | 1 | 2013 | 22 | 0.100 |
Why?
|
| alpha-Fetoproteins | 1 | 2014 | 125 | 0.100 |
Why?
|
| Orthopedic Fixation Devices | 1 | 2013 | 5 | 0.100 |
Why?
|
| Pulmonary Emphysema | 1 | 1994 | 96 | 0.100 |
Why?
|
| Peutz-Jeghers Syndrome | 1 | 2013 | 28 | 0.100 |
Why?
|
| Hepatic Artery | 1 | 2013 | 45 | 0.100 |
Why?
|
| Thiophenes | 1 | 2013 | 69 | 0.100 |
Why?
|
| Vascular Access Devices | 1 | 2013 | 31 | 0.100 |
Why?
|
| Adenoma | 1 | 2014 | 143 | 0.100 |
Why?
|
| Protease Inhibitors | 1 | 2013 | 93 | 0.100 |
Why?
|
| Insufflation | 1 | 2013 | 17 | 0.100 |
Why?
|
| Intestinal Neoplasms | 1 | 2013 | 36 | 0.100 |
Why?
|
| Mitogen-Activated Protein Kinase Phosphatases | 2 | 2010 | 15 | 0.090 |
Why?
|
| Colonic Neoplasms | 1 | 2015 | 262 | 0.090 |
Why?
|
| Dual-Specificity Phosphatases | 2 | 2010 | 24 | 0.090 |
Why?
|
| Needles | 1 | 2013 | 47 | 0.090 |
Why?
|
| Adrenalectomy | 1 | 2012 | 31 | 0.090 |
Why?
|
| Cyclopentanes | 2 | 1990 | 21 | 0.090 |
Why?
|
| Chronic Pain | 1 | 2015 | 164 | 0.090 |
Why?
|
| Decompression, Surgical | 1 | 2013 | 83 | 0.090 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2015 | 428 | 0.090 |
Why?
|
| Transcription Factors | 1 | 2002 | 2400 | 0.090 |
Why?
|
| Splenectomy | 1 | 2012 | 61 | 0.090 |
Why?
|
| Diagnostic Imaging | 1 | 2014 | 304 | 0.090 |
Why?
|
| Transfection | 2 | 2014 | 961 | 0.090 |
Why?
|
| Adenocarcinoma | 1 | 2019 | 968 | 0.090 |
Why?
|
| Purpura, Thrombocytopenic, Idiopathic | 1 | 2012 | 66 | 0.090 |
Why?
|
| Thalidomide | 1 | 2011 | 36 | 0.090 |
Why?
|
| Phosphorylation | 3 | 2010 | 1570 | 0.090 |
Why?
|
| Surveys and Questionnaires | 2 | 2026 | 4035 | 0.090 |
Why?
|
| Neoplasm, Residual | 2 | 2014 | 132 | 0.090 |
Why?
|
| Enzyme Inhibitors | 1 | 2014 | 559 | 0.080 |
Why?
|
| Pain Management | 1 | 2013 | 205 | 0.080 |
Why?
|
| Intestine, Small | 1 | 2013 | 291 | 0.080 |
Why?
|
| International Cooperation | 2 | 2022 | 161 | 0.080 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2025 | 3407 | 0.080 |
Why?
|
| Patient Safety | 1 | 2015 | 443 | 0.080 |
Why?
|
| Analgesics | 2 | 2022 | 119 | 0.080 |
Why?
|
| Benzimidazoles | 2 | 2009 | 155 | 0.080 |
Why?
|
| Embolization, Therapeutic | 1 | 2013 | 224 | 0.080 |
Why?
|
| Subarachnoid Space | 1 | 2010 | 23 | 0.080 |
Why?
|
| Respiratory Tract Fistula | 1 | 2010 | 15 | 0.080 |
Why?
|
| HLA-D Antigens | 1 | 1990 | 8 | 0.080 |
Why?
|
| Patched-1 Receptor | 2 | 2025 | 38 | 0.080 |
Why?
|
| Infusions, Intravenous | 7 | 2006 | 532 | 0.080 |
Why?
|
| Pleural Diseases | 1 | 2010 | 31 | 0.080 |
Why?
|
| Thoracic Surgery, Video-Assisted | 1 | 2010 | 51 | 0.080 |
Why?
|
| Attitude of Health Personnel | 1 | 2015 | 700 | 0.080 |
Why?
|
| Melanoma | 1 | 2017 | 927 | 0.080 |
Why?
|
| Pancreaticoduodenectomy | 2 | 2022 | 103 | 0.080 |
Why?
|
| Receptors, Cell Surface | 1 | 2011 | 419 | 0.080 |
Why?
|
| Aurora Kinases | 1 | 2009 | 27 | 0.080 |
Why?
|
| Reoperation | 4 | 2016 | 813 | 0.080 |
Why?
|
| Viral Matrix Proteins | 1 | 1990 | 108 | 0.080 |
Why?
|
| Antigens, Viral | 2 | 2002 | 394 | 0.070 |
Why?
|
| Neoplasm Invasiveness | 3 | 2017 | 630 | 0.070 |
Why?
|
| Benzazepines | 1 | 2009 | 43 | 0.070 |
Why?
|
| Antigen-Presenting Cells | 1 | 1990 | 123 | 0.070 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2009 | 88 | 0.070 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2002 | 688 | 0.070 |
Why?
|
| Thoracotomy | 1 | 2010 | 107 | 0.070 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2009 | 106 | 0.070 |
Why?
|
| Mutation | 6 | 2025 | 6068 | 0.070 |
Why?
|
| Antigens, Neoplasm | 2 | 2002 | 393 | 0.070 |
Why?
|
| Carboxylic Acids | 1 | 2008 | 19 | 0.070 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2009 | 137 | 0.070 |
Why?
|
| Immunity, Cellular | 1 | 1990 | 198 | 0.070 |
Why?
|
| Health Care Costs | 1 | 2012 | 406 | 0.070 |
Why?
|
| Receptors, Interleukin-6 | 1 | 2008 | 40 | 0.070 |
Why?
|
| Cisplatin | 2 | 2014 | 274 | 0.070 |
Why?
|
| Pyloric Stenosis, Hypertrophic | 1 | 2008 | 6 | 0.070 |
Why?
|
| Hematoma, Epidural, Spinal | 1 | 2008 | 5 | 0.070 |
Why?
|
| Morphine | 2 | 2022 | 80 | 0.070 |
Why?
|
| Umbilicus | 1 | 2008 | 13 | 0.070 |
Why?
|
| von Willebrand Diseases | 1 | 2009 | 54 | 0.070 |
Why?
|
| Lymphangioma | 1 | 2008 | 21 | 0.070 |
Why?
|
| Metabolic Clearance Rate | 5 | 2009 | 126 | 0.070 |
Why?
|
| Predictive Value of Tests | 2 | 2007 | 2289 | 0.070 |
Why?
|
| Oligopeptides | 1 | 2008 | 101 | 0.070 |
Why?
|
| Cost-Benefit Analysis | 2 | 2021 | 550 | 0.070 |
Why?
|
| Chromatography, High Pressure Liquid | 5 | 2011 | 316 | 0.070 |
Why?
|
| Mediastinal Neoplasms | 1 | 2008 | 36 | 0.070 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2008 | 59 | 0.070 |
Why?
|
| Receptors, Antigen, T-Cell | 2 | 2002 | 499 | 0.070 |
Why?
|
| Interleukin-1 | 1 | 2008 | 130 | 0.070 |
Why?
|
| Transcription Factor AP-1 | 1 | 2008 | 110 | 0.070 |
Why?
|
| Hernia, Inguinal | 2 | 1998 | 40 | 0.070 |
Why?
|
| Base Sequence | 2 | 2009 | 2729 | 0.070 |
Why?
|
| Genes, p53 | 1 | 2008 | 208 | 0.070 |
Why?
|
| Bone Marrow | 2 | 2008 | 317 | 0.070 |
Why?
|
| Pleural Effusion | 3 | 2013 | 103 | 0.060 |
Why?
|
| Molecular Sequence Data | 2 | 2009 | 3464 | 0.060 |
Why?
|
| Social Class | 2 | 2019 | 213 | 0.060 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2008 | 248 | 0.060 |
Why?
|
| Folic Acid Antagonists | 1 | 2006 | 16 | 0.060 |
Why?
|
| Minimally Invasive Surgical Procedures | 2 | 2021 | 193 | 0.060 |
Why?
|
| Parenchymal Tissue | 1 | 2026 | 8 | 0.060 |
Why?
|
| Pilot Projects | 2 | 2021 | 1439 | 0.060 |
Why?
|
| Glutamates | 1 | 2006 | 52 | 0.060 |
Why?
|
| Minichromosome Maintenance Complex Component 7 | 2 | 2006 | 5 | 0.060 |
Why?
|
| Sensitivity and Specificity | 4 | 2014 | 2076 | 0.060 |
Why?
|
| Guanine | 1 | 2006 | 58 | 0.060 |
Why?
|
| 3-Iodobenzylguanidine | 2 | 2017 | 12 | 0.060 |
Why?
|
| NF-kappa B | 1 | 2008 | 439 | 0.060 |
Why?
|
| Pulmonary Blastoma | 1 | 2006 | 11 | 0.060 |
Why?
|
| Germ-Line Mutation | 1 | 2008 | 371 | 0.060 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2014 | 3739 | 0.060 |
Why?
|
| Margins of Excision | 1 | 2026 | 60 | 0.060 |
Why?
|
| Drainage | 2 | 2013 | 246 | 0.060 |
Why?
|
| Neoplasms | 1 | 2020 | 2979 | 0.060 |
Why?
|
| Radiopharmaceuticals | 2 | 2017 | 155 | 0.060 |
Why?
|
| Protein Tyrosine Phosphatases | 1 | 2005 | 75 | 0.060 |
Why?
|
| Histamine H2 Antagonists | 1 | 2005 | 47 | 0.050 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2005 | 124 | 0.050 |
Why?
|
| Renal Dialysis | 2 | 2002 | 947 | 0.050 |
Why?
|
| Cyclin D1 | 1 | 2004 | 106 | 0.050 |
Why?
|
| Peptic Ulcer | 1 | 2005 | 148 | 0.050 |
Why?
|
| Nephroma, Mesoblastic | 1 | 2004 | 7 | 0.050 |
Why?
|
| Cyclins | 1 | 2004 | 93 | 0.050 |
Why?
|
| Breast Neoplasms | 1 | 2017 | 2597 | 0.050 |
Why?
|
| Topoisomerase I Inhibitors | 1 | 2004 | 16 | 0.050 |
Why?
|
| Carbazoles | 1 | 2004 | 30 | 0.050 |
Why?
|
| Depsipeptides | 1 | 2004 | 15 | 0.050 |
Why?
|
| Computational Biology | 1 | 2009 | 860 | 0.050 |
Why?
|
| Aged | 6 | 2019 | 20820 | 0.050 |
Why?
|
| Peptides, Cyclic | 1 | 2004 | 46 | 0.050 |
Why?
|
| Socioeconomic Factors | 2 | 2017 | 903 | 0.050 |
Why?
|
| Cells, Cultured | 1 | 2009 | 2884 | 0.050 |
Why?
|
| Camptothecin | 1 | 2004 | 76 | 0.050 |
Why?
|
| Heterografts | 2 | 2015 | 189 | 0.050 |
Why?
|
| Lymphatic Metastasis | 1 | 2004 | 425 | 0.050 |
Why?
|
| Middle Aged | 7 | 2019 | 28314 | 0.050 |
Why?
|
| Feasibility Studies | 1 | 2026 | 820 | 0.050 |
Why?
|
| T-Lymphocytes | 2 | 2002 | 1707 | 0.050 |
Why?
|
| Cell Line | 3 | 2001 | 2551 | 0.050 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2006 | 588 | 0.050 |
Why?
|
| Foreign-Body Migration | 2 | 2013 | 64 | 0.050 |
Why?
|
| Analysis of Variance | 2 | 2016 | 928 | 0.050 |
Why?
|
| Intercostal Nerves | 1 | 2022 | 7 | 0.050 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2022 | 57 | 0.050 |
Why?
|
| Educational Status | 1 | 2023 | 276 | 0.040 |
Why?
|
| Bays | 1 | 2021 | 7 | 0.040 |
Why?
|
| Models, Theoretical | 1 | 2004 | 358 | 0.040 |
Why?
|
| Neoplastic Stem Cells | 1 | 2004 | 329 | 0.040 |
Why?
|
| Catheter-Related Infections | 2 | 2014 | 137 | 0.040 |
Why?
|
| Arteriovenous Shunt, Surgical | 1 | 2002 | 86 | 0.040 |
Why?
|
| Kidney | 1 | 2008 | 1279 | 0.040 |
Why?
|
| Diagnosis-Related Groups | 1 | 2021 | 25 | 0.040 |
Why?
|
| Sternum | 1 | 2021 | 51 | 0.040 |
Why?
|
| Multivariate Analysis | 2 | 2015 | 1374 | 0.040 |
Why?
|
| Thoracoscopy | 1 | 2021 | 41 | 0.040 |
Why?
|
| Device Removal | 2 | 2013 | 222 | 0.040 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2015 | 1205 | 0.040 |
Why?
|
| Phenylacetates | 1 | 2001 | 26 | 0.040 |
Why?
|
| Prenatal Diagnosis | 1 | 2006 | 611 | 0.040 |
Why?
|
| Omentum | 1 | 2001 | 40 | 0.040 |
Why?
|
| Gangliosides | 1 | 2001 | 71 | 0.040 |
Why?
|
| Pharmaceutic Aids | 1 | 2000 | 2 | 0.040 |
Why?
|
| Knowledge | 1 | 2021 | 47 | 0.040 |
Why?
|
| Povidone | 1 | 2000 | 5 | 0.040 |
Why?
|
| Antibodies, Neoplasm | 1 | 2000 | 55 | 0.040 |
Why?
|
| Deoxycytidine | 1 | 2001 | 80 | 0.040 |
Why?
|
| Immunoglobulin Variable Region | 1 | 2000 | 52 | 0.040 |
Why?
|
| Pancreas | 1 | 2022 | 218 | 0.040 |
Why?
|
| Phenylbutyrates | 1 | 2001 | 54 | 0.040 |
Why?
|
| Severity of Illness Index | 2 | 2006 | 3025 | 0.040 |
Why?
|
| Cefazolin | 1 | 2000 | 19 | 0.040 |
Why?
|
| Operative Time | 1 | 2021 | 199 | 0.040 |
Why?
|
| Fallopian Tubes | 1 | 2001 | 66 | 0.040 |
Why?
|
| Chemokines, C | 1 | 2000 | 10 | 0.040 |
Why?
|
| Isoflurane | 1 | 2000 | 35 | 0.040 |
Why?
|
| Sialoglycoproteins | 1 | 2000 | 43 | 0.040 |
Why?
|
| Pleurodesis | 1 | 2020 | 15 | 0.040 |
Why?
|
| Anesthetics, Inhalation | 1 | 2000 | 41 | 0.040 |
Why?
|
| HLA-A1 Antigen | 1 | 2000 | 2 | 0.040 |
Why?
|
| Intestinal Perforation | 1 | 2000 | 51 | 0.040 |
Why?
|
| Chest Tubes | 1 | 2020 | 38 | 0.040 |
Why?
|
| Lymphokines | 1 | 2000 | 62 | 0.040 |
Why?
|
| Registries | 2 | 2019 | 1607 | 0.040 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2006 | 747 | 0.040 |
Why?
|
| Infant, Premature | 1 | 2006 | 861 | 0.040 |
Why?
|
| Neoplasm Metastasis | 2 | 2017 | 713 | 0.040 |
Why?
|
| Gene Expression Regulation | 1 | 2008 | 2322 | 0.040 |
Why?
|
| Program Development | 1 | 2021 | 179 | 0.040 |
Why?
|
| Phenylenediamines | 1 | 2000 | 29 | 0.040 |
Why?
|
| Imidazoles | 1 | 2021 | 219 | 0.040 |
Why?
|
| Cephalosporins | 1 | 2000 | 135 | 0.040 |
Why?
|
| Penicillins | 1 | 2000 | 154 | 0.040 |
Why?
|
| Brefeldin A | 2 | 1990 | 11 | 0.040 |
Why?
|
| Epitopes | 1 | 2001 | 323 | 0.040 |
Why?
|
| Peritonitis | 2 | 2013 | 75 | 0.040 |
Why?
|
| Resource Allocation | 1 | 2019 | 53 | 0.040 |
Why?
|
| Interleukin-2 | 1 | 2000 | 235 | 0.040 |
Why?
|
| Pyloric Stenosis | 1 | 1999 | 8 | 0.040 |
Why?
|
| Datasets as Topic | 1 | 2019 | 98 | 0.040 |
Why?
|
| Age of Onset | 1 | 2001 | 592 | 0.040 |
Why?
|
| Adenoma, Islet Cell | 1 | 2019 | 5 | 0.040 |
Why?
|
| Up-Regulation | 1 | 2002 | 823 | 0.040 |
Why?
|
| Endoplasmic Reticulum | 2 | 1991 | 208 | 0.040 |
Why?
|
| Buprenorphine | 1 | 2000 | 112 | 0.040 |
Why?
|
| Infant, Very Low Birth Weight | 1 | 2000 | 169 | 0.040 |
Why?
|
| Feeding Methods | 1 | 1999 | 35 | 0.040 |
Why?
|
| Herpesvirus 4, Human | 1 | 2002 | 639 | 0.040 |
Why?
|
| Autonomic Nervous System Diseases | 1 | 1999 | 41 | 0.040 |
Why?
|
| Ganciclovir | 1 | 1999 | 101 | 0.040 |
Why?
|
| Genetic Therapy | 2 | 2000 | 711 | 0.040 |
Why?
|
| Emergency Service, Hospital | 2 | 2017 | 1212 | 0.040 |
Why?
|
| Half-Life | 2 | 2010 | 148 | 0.030 |
Why?
|
| Comorbidity | 2 | 2018 | 1584 | 0.030 |
Why?
|
| Time-to-Treatment | 1 | 2020 | 208 | 0.030 |
Why?
|
| General Surgery | 1 | 2021 | 224 | 0.030 |
Why?
|
| Promoter Regions, Genetic | 1 | 2002 | 1208 | 0.030 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 2013 | 290 | 0.030 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 1999 | 81 | 0.030 |
Why?
|
| B-Lymphocytes | 1 | 2000 | 508 | 0.030 |
Why?
|
| Adenoviridae | 1 | 2000 | 581 | 0.030 |
Why?
|
| Fellowships and Scholarships | 1 | 2021 | 325 | 0.030 |
Why?
|
| Patient Readmission | 1 | 2021 | 436 | 0.030 |
Why?
|
| Immunotherapy, Adoptive | 2 | 2002 | 950 | 0.030 |
Why?
|
| Response Evaluation Criteria in Solid Tumors | 1 | 2017 | 9 | 0.030 |
Why?
|
| Administration, Oral | 2 | 2010 | 706 | 0.030 |
Why?
|
| Enterocolitis, Necrotizing | 1 | 2000 | 257 | 0.030 |
Why?
|
| Gastroschisis | 1 | 1998 | 57 | 0.030 |
Why?
|
| Length of Stay | 2 | 2013 | 1406 | 0.030 |
Why?
|
| Adrenal Cortex Hormones | 2 | 2012 | 331 | 0.030 |
Why?
|
| Deglutition Disorders | 1 | 2018 | 132 | 0.030 |
Why?
|
| Medically Uninsured | 1 | 2017 | 79 | 0.030 |
Why?
|
| Chemoradiotherapy, Adjuvant | 1 | 2016 | 30 | 0.030 |
Why?
|
| Intraoperative Complications | 1 | 1998 | 153 | 0.030 |
Why?
|
| Injections, Intravenous | 2 | 2008 | 237 | 0.030 |
Why?
|
| Colectomy | 1 | 2017 | 89 | 0.030 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2017 | 122 | 0.030 |
Why?
|
| Regression Analysis | 1 | 2018 | 759 | 0.030 |
Why?
|
| Transduction, Genetic | 3 | 2002 | 276 | 0.030 |
Why?
|
| Incidental Findings | 1 | 2017 | 122 | 0.030 |
Why?
|
| Operating Rooms | 1 | 2016 | 73 | 0.030 |
Why?
|
| Needs Assessment | 1 | 2017 | 173 | 0.030 |
Why?
|
| Lymph Node Excision | 1 | 2016 | 158 | 0.030 |
Why?
|
| Tandem Repeat Sequences | 1 | 2015 | 37 | 0.030 |
Why?
|
| Silver Sulfadiazine | 1 | 1995 | 9 | 0.030 |
Why?
|
| Nylons | 1 | 1995 | 10 | 0.030 |
Why?
|
| Silicones | 1 | 1995 | 30 | 0.030 |
Why?
|
| Immunoblotting | 1 | 2015 | 291 | 0.030 |
Why?
|
| Appendix | 1 | 2015 | 11 | 0.030 |
Why?
|
| Multidetector Computed Tomography | 1 | 2015 | 33 | 0.030 |
Why?
|
| Immobilization | 1 | 1995 | 15 | 0.030 |
Why?
|
| Aged, 80 and over | 2 | 2017 | 6765 | 0.030 |
Why?
|
| Tachycardia, Ventricular | 1 | 1998 | 258 | 0.030 |
Why?
|
| Consolidation Chemotherapy | 1 | 2014 | 7 | 0.030 |
Why?
|
| Immunotherapy | 1 | 2000 | 758 | 0.030 |
Why?
|
| Recurrence | 2 | 2014 | 1475 | 0.030 |
Why?
|
| Salivary Gland Neoplasms | 1 | 2015 | 63 | 0.030 |
Why?
|
| Mechanistic Target of Rapamycin Complex 2 | 1 | 2015 | 32 | 0.030 |
Why?
|
| Risk | 2 | 2012 | 723 | 0.030 |
Why?
|
| Skin Transplantation | 1 | 1995 | 56 | 0.030 |
Why?
|
| Nervous System Diseases | 1 | 2018 | 392 | 0.030 |
Why?
|
| Necrosis | 1 | 2015 | 193 | 0.030 |
Why?
|
| Radionuclide Imaging | 1 | 2014 | 113 | 0.030 |
Why?
|
| Consensus | 1 | 2017 | 521 | 0.030 |
Why?
|
| Carboplatin | 1 | 2014 | 79 | 0.030 |
Why?
|
| Chi-Square Distribution | 1 | 2015 | 563 | 0.030 |
Why?
|
| Cause of Death | 1 | 2017 | 501 | 0.030 |
Why?
|
| Carcinoma, Papillary | 1 | 2015 | 91 | 0.030 |
Why?
|
| Intraoperative Care | 1 | 2015 | 123 | 0.030 |
Why?
|
| Gene Expression Profiling | 2 | 2015 | 1800 | 0.030 |
Why?
|
| Mass Spectrometry | 2 | 2006 | 358 | 0.030 |
Why?
|
| Antibodies, Monoclonal | 1 | 2000 | 976 | 0.030 |
Why?
|
| Mechanistic Target of Rapamycin Complex 1 | 1 | 2015 | 178 | 0.030 |
Why?
|
| Adenine | 1 | 2015 | 119 | 0.030 |
Why?
|
| Herpes Simplex Virus Protein Vmw65 | 1 | 2013 | 11 | 0.030 |
Why?
|
| Gene Duplication | 1 | 2015 | 358 | 0.030 |
Why?
|
| Ubiquitin-Specific Peptidase 7 | 1 | 2013 | 17 | 0.030 |
Why?
|
| Adenosine Triphosphate | 1 | 2015 | 265 | 0.030 |
Why?
|
| Resorcinols | 1 | 2013 | 7 | 0.030 |
Why?
|
| Sex Distribution | 1 | 2014 | 317 | 0.030 |
Why?
|
| Clinical Competence | 1 | 2021 | 1042 | 0.030 |
Why?
|
| Analgesia, Patient-Controlled | 1 | 2013 | 13 | 0.030 |
Why?
|
| Cerebrospinal Fluid | 2 | 2004 | 99 | 0.030 |
Why?
|
| Algorithms | 2 | 2005 | 1662 | 0.030 |
Why?
|
| Active Transport, Cell Nucleus | 1 | 2014 | 113 | 0.030 |
Why?
|
| Delayed Diagnosis | 1 | 2015 | 130 | 0.020 |
Why?
|
| SEER Program | 1 | 2014 | 213 | 0.020 |
Why?
|
| Lactones | 1 | 2013 | 39 | 0.020 |
Why?
|
| Clavicle | 1 | 2013 | 10 | 0.020 |
Why?
|
| Sphincterotomy, Endoscopic | 1 | 2013 | 11 | 0.020 |
Why?
|
| Hemothorax | 1 | 2013 | 16 | 0.020 |
Why?
|
| Hydrocodone | 1 | 2013 | 36 | 0.020 |
Why?
|
| Hemoperitoneum | 1 | 2013 | 9 | 0.020 |
Why?
|
| Diet, Fat-Restricted | 1 | 2013 | 36 | 0.020 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2015 | 236 | 0.020 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2015 | 525 | 0.020 |
Why?
|
| Antiviral Agents | 1 | 1999 | 802 | 0.020 |
Why?
|
| Lacerations | 1 | 2013 | 30 | 0.020 |
Why?
|
| Genomics | 1 | 2021 | 1618 | 0.020 |
Why?
|
| Bicycling | 1 | 2013 | 37 | 0.020 |
Why?
|
| alpha 1-Antitrypsin Deficiency | 1 | 2013 | 44 | 0.020 |
Why?
|
| Bile Ducts | 1 | 2013 | 52 | 0.020 |
Why?
|
| Surgical Flaps | 1 | 1995 | 179 | 0.020 |
Why?
|
| Disease Management | 1 | 2017 | 554 | 0.020 |
Why?
|
| Sex Factors | 1 | 2017 | 1342 | 0.020 |
Why?
|
| Thoracic Wall | 1 | 2013 | 40 | 0.020 |
Why?
|
| Enzyme Activation | 1 | 2014 | 576 | 0.020 |
Why?
|
| Radiography, Interventional | 1 | 2013 | 78 | 0.020 |
Why?
|
| Sequence Analysis, RNA | 1 | 2015 | 408 | 0.020 |
Why?
|
| Cholangiopancreatography, Endoscopic Retrograde | 1 | 2013 | 80 | 0.020 |
Why?
|
| Rho(D) Immune Globulin | 1 | 2012 | 14 | 0.020 |
Why?
|
| Meckel Diverticulum | 1 | 1992 | 10 | 0.020 |
Why?
|
| Hematoma | 1 | 2013 | 85 | 0.020 |
Why?
|
| Analgesics, Non-Narcotic | 1 | 2013 | 78 | 0.020 |
Why?
|
| Acetaminophen | 1 | 2013 | 99 | 0.020 |
Why?
|
| Bites and Stings | 1 | 2012 | 29 | 0.020 |
Why?
|
| Cyclophosphamide | 1 | 2014 | 425 | 0.020 |
Why?
|
| Fluid Therapy | 1 | 2013 | 140 | 0.020 |
Why?
|
| Platelet Count | 1 | 2012 | 139 | 0.020 |
Why?
|
| Isoantibodies | 1 | 2012 | 62 | 0.020 |
Why?
|
| Patched Receptors | 1 | 2011 | 27 | 0.020 |
Why?
|
| Drug Costs | 1 | 2012 | 63 | 0.020 |
Why?
|
| Pain Measurement | 1 | 2013 | 348 | 0.020 |
Why?
|
| Wound Infection | 1 | 2012 | 58 | 0.020 |
Why?
|
| Abdominal Injuries | 1 | 2013 | 120 | 0.020 |
Why?
|
| Suture Techniques | 1 | 2013 | 175 | 0.020 |
Why?
|
| Ultrasonography, Prenatal | 1 | 1997 | 969 | 0.020 |
Why?
|
| Body Weight | 1 | 2016 | 985 | 0.020 |
Why?
|
| Biopsy, Needle | 1 | 2012 | 204 | 0.020 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2012 | 148 | 0.020 |
Why?
|
| Dogs | 1 | 2012 | 615 | 0.020 |
Why?
|
| Hypotension | 1 | 2013 | 186 | 0.020 |
Why?
|
| Golgi Apparatus | 1 | 1991 | 92 | 0.020 |
Why?
|
| Blood Transfusion | 1 | 2013 | 292 | 0.020 |
Why?
|
| Wounds, Nonpenetrating | 1 | 2013 | 215 | 0.020 |
Why?
|
| Diagnostic Errors | 1 | 2015 | 342 | 0.020 |
Why?
|
| Intestines | 1 | 2015 | 587 | 0.020 |
Why?
|
| Surgical Wound Infection | 1 | 2013 | 264 | 0.020 |
Why?
|
| Thiourea | 1 | 2010 | 9 | 0.020 |
Why?
|
| Fibrin Tissue Adhesive | 1 | 2010 | 9 | 0.020 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2016 | 774 | 0.020 |
Why?
|
| Immunocompromised Host | 1 | 2012 | 310 | 0.020 |
Why?
|
| Chloroquine | 1 | 1990 | 30 | 0.020 |
Why?
|
| Sequence Analysis, DNA | 1 | 2015 | 1690 | 0.020 |
Why?
|
| Major Histocompatibility Complex | 1 | 1990 | 48 | 0.020 |
Why?
|
| DNA Mutational Analysis | 1 | 2011 | 777 | 0.020 |
Why?
|
| Serine | 1 | 2010 | 161 | 0.020 |
Why?
|
| Logistic Models | 1 | 2014 | 1794 | 0.020 |
Why?
|
| Biological Transport | 1 | 1990 | 328 | 0.020 |
Why?
|
| Chromatography, Liquid | 1 | 2010 | 232 | 0.020 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 1 | 2009 | 40 | 0.020 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 2009 | 62 | 0.020 |
Why?
|
| Cytoplasm | 1 | 1990 | 248 | 0.020 |
Why?
|
| Cytosol | 1 | 1989 | 135 | 0.020 |
Why?
|
| Influenza A virus | 1 | 1990 | 142 | 0.020 |
Why?
|
| In Vitro Techniques | 1 | 1990 | 808 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2015 | 3349 | 0.020 |
Why?
|
| Piperazines | 1 | 2010 | 269 | 0.020 |
Why?
|
| Molecular Structure | 1 | 2009 | 311 | 0.020 |
Why?
|
| Immunosuppressive Agents | 1 | 2012 | 656 | 0.020 |
Why?
|
| Hospitalization | 1 | 2017 | 1935 | 0.020 |
Why?
|
| International Classification of Diseases | 1 | 2008 | 91 | 0.020 |
Why?
|
| Protein Structure, Secondary | 1 | 2008 | 235 | 0.020 |
Why?
|
| Ligation | 2 | 1998 | 133 | 0.020 |
Why?
|
| Thoracic Vertebrae | 1 | 2008 | 74 | 0.020 |
Why?
|
| Chronic Disease | 1 | 2012 | 1241 | 0.020 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2010 | 286 | 0.020 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2009 | 352 | 0.020 |
Why?
|
| Cervical Vertebrae | 1 | 2008 | 101 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2014 | 2890 | 0.020 |
Why?
|
| Kinetics | 1 | 2009 | 1085 | 0.020 |
Why?
|
| Amino Acid Substitution | 1 | 2008 | 404 | 0.020 |
Why?
|
| HeLa Cells | 1 | 2008 | 689 | 0.020 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 1990 | 501 | 0.020 |
Why?
|
| Pemetrexed | 1 | 2006 | 8 | 0.020 |
Why?
|
| Embryo, Mammalian | 1 | 2008 | 404 | 0.020 |
Why?
|
| Prodrugs | 1 | 2006 | 56 | 0.020 |
Why?
|
| Tetradecanoylphorbol Acetate | 1 | 2006 | 56 | 0.010 |
Why?
|
| 9,10-Dimethyl-1,2-benzanthracene | 1 | 2006 | 53 | 0.010 |
Why?
|
| Genes, ras | 1 | 2006 | 95 | 0.010 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2014 | 1273 | 0.010 |
Why?
|
| Carcinogens | 1 | 2006 | 128 | 0.010 |
Why?
|
| Adenine Nucleotides | 1 | 2005 | 36 | 0.010 |
Why?
|
| Liver | 1 | 2013 | 1783 | 0.010 |
Why?
|
| Vagotomy | 1 | 2005 | 10 | 0.010 |
Why?
|
| Peptic Ulcer Hemorrhage | 1 | 2005 | 18 | 0.010 |
Why?
|
| Peptic Ulcer Perforation | 1 | 2005 | 14 | 0.010 |
Why?
|
| Gastric Outlet Obstruction | 1 | 2005 | 14 | 0.010 |
Why?
|
| Pyloric Antrum | 1 | 2005 | 62 | 0.010 |
Why?
|
| Neoplasms, Experimental | 1 | 2006 | 201 | 0.010 |
Why?
|
| Models, Biological | 1 | 2010 | 1375 | 0.010 |
Why?
|
| COS Cells | 1 | 2005 | 253 | 0.010 |
Why?
|
| Cyclin D3 | 1 | 2004 | 11 | 0.010 |
Why?
|
| N-Myc Proto-Oncogene Protein | 1 | 2005 | 57 | 0.010 |
Why?
|
| Cyclin D2 | 1 | 2004 | 14 | 0.010 |
Why?
|
| Mitoxantrone | 1 | 2004 | 28 | 0.010 |
Why?
|
| Pedigree | 1 | 2008 | 1670 | 0.010 |
Why?
|
| Substrate Specificity | 1 | 2005 | 285 | 0.010 |
Why?
|
| Catalytic Domain | 1 | 2005 | 160 | 0.010 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2006 | 387 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2004 | 61 | 0.010 |
Why?
|
| Retinoblastoma Protein | 1 | 2004 | 78 | 0.010 |
Why?
|
| Cyclin-Dependent Kinases | 1 | 2004 | 82 | 0.010 |
Why?
|
| Oncogene Proteins | 1 | 2005 | 136 | 0.010 |
Why?
|
| Cyclin-Dependent Kinase 6 | 1 | 2004 | 50 | 0.010 |
Why?
|
| Antigens, Surface | 1 | 2004 | 112 | 0.010 |
Why?
|
| Hypertension, Renal | 1 | 2004 | 30 | 0.010 |
Why?
|
| DNA Primers | 1 | 2005 | 600 | 0.010 |
Why?
|
| Gastrectomy | 1 | 2005 | 104 | 0.010 |
Why?
|
| Cyclin-Dependent Kinase 4 | 1 | 2004 | 66 | 0.010 |
Why?
|
| Paraneoplastic Syndromes | 1 | 2004 | 13 | 0.010 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2005 | 623 | 0.010 |
Why?
|
| Hypercalcemia | 1 | 2004 | 41 | 0.010 |
Why?
|
| Fibroblasts | 1 | 2008 | 850 | 0.010 |
Why?
|
| Cloning, Molecular | 1 | 2005 | 779 | 0.010 |
Why?
|
| Hematuria | 1 | 2004 | 48 | 0.010 |
Why?
|
| Mutation, Missense | 1 | 2008 | 920 | 0.010 |
Why?
|
| Hydrops Fetalis | 1 | 2004 | 82 | 0.010 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 2004 | 194 | 0.010 |
Why?
|
| Fluorescent Dyes | 1 | 2004 | 246 | 0.010 |
Why?
|
| Blood-Brain Barrier | 1 | 2004 | 153 | 0.010 |
Why?
|
| Ureter | 1 | 2004 | 84 | 0.010 |
Why?
|
| Graft Occlusion, Vascular | 1 | 2002 | 79 | 0.010 |
Why?
|
| Protein Binding | 1 | 2006 | 1649 | 0.010 |
Why?
|
| Flow Cytometry | 1 | 2004 | 764 | 0.010 |
Why?
|
| Cell Cycle | 1 | 2004 | 593 | 0.010 |
Why?
|
| Meningeal Neoplasms | 1 | 2004 | 217 | 0.010 |
Why?
|
| Treatment Failure | 1 | 2002 | 346 | 0.010 |
Why?
|
| Coculture Techniques | 1 | 2002 | 229 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 2005 | 2392 | 0.010 |
Why?
|
| Equipment Failure | 1 | 2001 | 122 | 0.010 |
Why?
|
| Genetic Engineering | 1 | 2001 | 161 | 0.010 |
Why?
|
| Mice, Transgenic | 1 | 2006 | 2330 | 0.010 |
Why?
|
| Antibody Specificity | 1 | 2000 | 164 | 0.010 |
Why?
|
| Mice, Knockout | 1 | 2008 | 3807 | 0.010 |
Why?
|
| Probability | 1 | 2000 | 305 | 0.010 |
Why?
|
| Gene Expression | 1 | 2004 | 1480 | 0.010 |
Why?
|
| Catheterization, Peripheral | 1 | 2001 | 118 | 0.010 |
Why?
|
| Lymphocyte Activation | 1 | 2002 | 630 | 0.010 |
Why?
|
| Benzamides | 1 | 2000 | 125 | 0.010 |
Why?
|
| Hypertrophy | 1 | 1999 | 99 | 0.010 |
Why?
|
| Phosphopyruvate Hydratase | 1 | 1999 | 21 | 0.010 |
Why?
|
| S100 Proteins | 1 | 1999 | 40 | 0.010 |
Why?
|
| Gene Transfer Techniques | 1 | 2000 | 344 | 0.010 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2001 | 211 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2008 | 4637 | 0.010 |
Why?
|
| Thrombosis | 1 | 2002 | 498 | 0.010 |
Why?
|
| Amiodarone | 1 | 1998 | 47 | 0.010 |
Why?
|
| Intensive Care Units, Neonatal | 1 | 2000 | 350 | 0.010 |
Why?
|
| Electric Countershock | 1 | 1998 | 73 | 0.010 |
Why?
|
| Anti-Arrhythmia Agents | 1 | 1998 | 230 | 0.010 |
Why?
|
| Cytokines | 1 | 2001 | 1330 | 0.010 |
Why?
|
| Nocodazole | 1 | 1991 | 11 | 0.010 |
Why?
|
| Centrifugation, Density Gradient | 1 | 1991 | 54 | 0.010 |
Why?
|
| Cell Fractionation | 1 | 1991 | 22 | 0.010 |
Why?
|
| Immunoenzyme Techniques | 1 | 1991 | 235 | 0.010 |
Why?
|
| Cricetinae | 1 | 1991 | 361 | 0.010 |
Why?
|
| Microscopy, Electron | 1 | 1991 | 305 | 0.010 |
Why?
|
| Fluorescent Antibody Technique | 1 | 1991 | 411 | 0.010 |
Why?
|
| Acute Disease | 1 | 1992 | 1153 | 0.000 |
Why?
|
| Pregnancy | 1 | 1997 | 7389 | 0.000 |
Why?
|